Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

Back to Contracts

Antibody Development & Licensing

Active

Federal

Response Deadline12/16/2026, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract involves the development, validation, and commercialization of monoclonal antibodies that specifically target bacterial membrane lipids. This work utilizes a nanodisc platform, which serves either as an immunogen or a screening tool, to enhance the effectiveness of antibody generation and assessment. The effort is positioned as a subcontract under the Department of Energy's Triad contractor, emphasizing a focus on innovative biotechnological approaches within a government research context. Work will be performed in Los Alamos, with the solicitation posted in mid-2026 and a response deadline toward the end of that year. The contract falls under NAICS code 541711, indicating its alignment with research and development in the physical, engineering, and life sciences. Although specific organizational and contact details are not provided, the contract is geared toward advancing antibody technologies through a combination of advanced immunological platforms and commercial application strategies.

General Info

Development and commercialization of monoclonal antibodies targeting bacterial lipids using nanodisc technology.

Agency

Department Of Energy → Triad - DOE ContractorView Agency

NAICS

541711 - Research and Development in BiotechnologyView NAICS

Place of Performance

Los Alamos, NM, 87545, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJun 15

subcontract

Response DeadlineDec 16

Submission deadline

Response Deadline

12/16/2026, 12:00:00 AM UTCin 5 months

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Energy → Triad - DOE Contractor

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Energy → Triad - DOE Contractor

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Develop, validate, and commercialize monoclonal antibodies targeting bacterial membrane lipids using the nanodisc platform as an immunogen or screening tool.

Similar Contracts

Same NAICS industry code

Phase 2/3 Clinical Trial ExecutionThe contract pertains to the execution of Phase 2/3 clinical trials focused on acute pain management, requiring full management of trial operations including site selection, patient recruitment, data collection, and safety monitoring in strict compliance with FDA regulations. The work will be performed in Frederick, Maryland, with a post date of June 29, 2026, and a response deadline of July 30, 2026, at 5:00 PM. This is a subcontract under the Defense Health Agency, part of the Department of Defense, and falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. All activities must adhere to regulatory standards to ensure trial integrity, patient safety, and data reliability, with performance centered in Frederick, MD.

Defense Health Agency

POSTED

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Data Management and Evaluation SupportThe contract titled Data Management and Evaluation Support is a subcontract under the Administration for Community Living, part of the Department of Health and Human Services, aimed at providing comprehensive support for the collection, management, analysis, and evaluation of research and program outcomes. The work must strictly adhere to federal standards to ensure data integrity, compliance, and quality reporting, with a focus on delivering actionable insights that inform program effectiveness and decision-making. The North American Industry Classification System code 541711 identifies this as scientific research and development services, underscoring the technical and analytical nature of the required efforts. Proposals must be submitted by the deadline of July 29, 2026, with the opportunity posted on June 22, 2026. The place of performance and specific office address are not specified, indicating flexibility in where the work may be conducted, though it must align with federal operational requirements. No set-aside type is designated, meaning the subcontract is open to all eligible subcontractors without preference for small businesses or other categories. Interested parties should review the official solicitation link for detailed submission guidelines and technical requirements, as success will depend on demonstrating robust methodologies in data handling, analytical rigor, and compliance with federal regulations governing research and program evaluation.

Administration For Community Living

POSTED

about 1 month ago

DEADLINE

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

Clinical Trial Design and Biostatistical SupportThe contract seeks specialized expertise to support clinical trial design and biostatistical analysis for orthopaedic trauma research funded by the Department of Defense, specifically under the U.S. Army Medical Research and Acquisition Activity. The work involves developing robust clinical trial methodologies, crafting statistical analysis plans, performing power analyses to ensure adequate sample sizes, and establishing data monitoring frameworks to ensure trial integrity and compliance with regulatory standards. Support must be tailored to the unique challenges of military-relevant trauma studies, including patient populations, deployment-related injuries, and the operational constraints of DoD medical settings. The opportunity is structured as a subcontract with a NAICS code of 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, and responses are due by November 18, 2026. Performance is expected to occur within the broader DoD infrastructure, though no specific location is designated. There is no set-aside classification specified, and the contract is open to qualified entities capable of delivering high-level biostatistical and clinical trial methodological support in a defense medical research context.

Department Of The Army -- Usamraa

POSTED

about 1 month ago

DEADLINE

Preclinical Biomedical Research on Traumatic Orthopaedic InjuriesThis contract requires the conduct of preclinical biomedical research focused on bone healing, tissue regeneration, and orthopaedic trauma models using animal systems, with the goal of advancing medical solutions aligned with military needs. The work involves designing controlled experiments, collecting longitudinal data on injury response and recovery, and performing rigorous statistical and biological analysis to evaluate therapeutic interventions. All research must be tailored to simulate combat-related orthopaedic injuries and produce actionable insights applicable to field medical care and soldier recovery protocols. The effort is structured as a subcontract under the Department of the Army through USAMRAA, with a solicitation posted on June 17, 2026, and a response deadline of November 18, 2026. The project falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. Performance location and point of contact details are not specified, but the research must be executed in facilities capable of supporting high-standard animal modeling and biomechanical analysis. The ultimate objective is to generate validated preclinical data to inform the development of next-generation treatments for traumatic injuries sustained in military operations.

Department Of The Army -- Usamraa

POSTED

about 1 month ago

DEADLINE

Nanobody-Drug Conjugate Systems DevelopmentThe contract pertains to the licensing of the NanoFET platform to develop targeted nanobody-drug conjugates for the precision delivery of therapeutics using a modular scaffold designed to enhance specificity and efficiency in therapeutic distribution. This subcontract, issued by the Department of Energy through its contractor Triad, enables the recipient to leverage the proprietary NanoFET technology for advancing next-generation drug delivery systems with a focus on oncology and other targeted disease treatments. The project is centered in Los Alamos, New Mexico, with a response deadline of December 18, 2026, and falls under the NAICS code 541711 for research and development in biotechnology. The modular scaffold allows for customizable conjugation of nanobodies with therapeutic payloads, facilitating high-affinity targeting of disease markers while minimizing off-target effects. The agreement emphasizes technological innovation and the translation of advanced nanoscale platforms into clinically viable delivery systems.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

Infectious Disease Vaccine DevelopmentThe contract involves licensing the NanoFET platform to enable rapid-response vaccine development against viral and bacterial pathogens, leveraging its unique adjuvant-free immune activation and modular antigen integration capabilities. This technology allows for swift adaptation to emerging infectious threats by streamlining the design and production of vaccines without relying on traditional immune-stimulating additives, significantly reducing development timelines and enhancing safety profiles. The work is structured as a subcontract under the Department of Energy, with performance centered at Los Alamos, New Mexico, and is targeted toward advancing national defense and public health preparedness through next-generation vaccine platforms. The opportunity is open for proposals until December 18, 2026, and falls under NAICS code 541711, indicating it targets research and development in the physical, engineering, and life sciences. The contracting entity is Triad, the DOE Contractor, and the initiative aligns with broader federal efforts to build resilient, scalable biodefense capabilities. Participants must demonstrate technical proficiency in the NanoFET platform, experience in infectious disease vaccine design, and the capacity to execute rapid development cycles under strict timelines. Success in this effort will contribute directly to scalable, next-generation immunization technologies capable of addressing current and future biological threats.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

Modular Cancer Immunotherapy DevelopmentThe contract entails the license and development of the NanoFET platform for the creation of targeted cancer immunotherapies, leveraging its modular scaffold to deliver tumor-specific antigens and immune stimulators in a precise and effective manner. The work is focused on advancing next-generation immunotherapeutic approaches by engineering the platform to enhance immune recognition and response against cancer cells, with the goal of improving therapeutic outcomes and reducing off-target effects. The project requires collaboration to optimize the platform’s design, validate its efficacy in preclinical models, and prepare for subsequent clinical translation, all grounded in cutting-edge nanotechnology and immunological science. The contract is a subcontract under the Department of Energy, with performance centered in Los Alamos, New Mexico, 87545, and is classified under NAICS code 541711 for research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, with a response deadline of December 18, 2026, indicating a strategic timeline for proposal submission and evaluation. While details on set-aside status and point of contact are not provided, the project is positioned to align with national priorities in advanced biomedical innovation and cancer treatment, leveraging federal research infrastructure and expertise to drive transformative therapeutic solutions.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

Preclinical Research & Immunogenicity TestingThe contract involves the execution of binding assays, immune stimulation studies, and antigen identification leveraging the nanodisc platform, aimed at advancing vaccine or therapeutic development. This subcontract, titled "Preclinical Research & Immunogenicity Testing," is to support work primarily focused on preclinical stages of research, targeting immune responses and antigen characterization to facilitate the creation of effective medical interventions. Issued by the Department of Energy through its contractor Triad, the work is to be performed in Los Alamos, with a deadline for responses by mid-December 2026. Classified under NAICS code 541711, which pertains to research and development in biotechnology, the contract does not specify any particular set-aside requirements or organization type constraints. The research efforts under this agreement are expected to play a critical role in underpinning DOE-supported vaccine and therapeutic programs, emphasizing innovative assay platforms like nanodiscs to enhance scientific understanding and product development.

Triad - DOE Contractor

POSTED

about 1 month ago

DEADLINE

More opportunities from Department Of Energy → Triad - DOE Contractor

Same awarding agency

TECHNOLOGY LICENSING OPPORTUNITY: ScreenFlow Liquid-Liquid MicrocontactorScreenFlow is a microfluidic liquid-liquid contactor that enables efficient, membrane-free mixing and separation of immiscible fluids using paired wettable screens and printed-in gaskets, eliminating the need for fragile microchips or permeable membranes. The design features one hydrophilic screen for aqueous streams and one hydrophobic, oleophilic screen for organic streams, which intersect in overlapping regions to form a stable, capillary-held interface where mass transfer occurs while bulk fluids remain separated. This architecture supports both co-current and counter-current flow, scales linearly by stacking additional screen layers to achieve flow rates from microliters to milliliters per minute, and is fabricated using standard machine-shop tools and off-the-shelf materials, making it accessible and cost-effective. The printed-gasket variant reduces part count by nearly half, simplifies assembly, and eliminates edge leakage, enabling stable, continuous operation over days without degradation, which is critical for industrial extraction, purification, and sample-handling workflows. The technology targets high-value applications including rare-earth and trace-element recovery, pharmaceutical continuous manufacturing, petroleum refining, analytical sample preparation, food and beverage processing such as decaffeination, and water treatment for contaminant removal. With a Technology Readiness Level of 4, ScreenFlow is patent-pending and builds upon an existing U.S. patent, offering exclusive or non-exclusive licensing opportunities through Los Alamos National Laboratory. The system’s robustness, scalability, and compatibility with conventional manufacturing make it ideal for commercialization in industries requiring precise, high-throughput biphasic processing without the complexity or fragility of traditional microfluidic platforms. Proposals must be submitted by August 7, 2026, with inquiries directed to the licensing office at Los Alamos National Laboratory.

POSTED

DEADLINE

TECHNOLOGY LICENSING OPPORTUNITY: Acid-tuned Terphenyl Membranes (ATM)Acid-tuned Terphenyl Membranes (ATM) is a breakthrough hydrocarbon-based proton exchange membrane technology developed by Los Alamos National Laboratory that redefines how proton conductivity is achieved without relying on excessive sulfonation. By incorporating a precisely placed fluorinated electron-withdrawing unit adjacent to each sulfonic acid group on a rigid terphenyl backbone, the membrane enhances the intrinsic acidity of each proton-carrying site, enabling higher proton conductivity—87 mS/cm at 80°C under full humidity—while simultaneously reducing water uptake by over 60% compared to conventional analogs. This molecular-level innovation delivers superior dimensional stability and mechanical durability, addressing the core weaknesses of traditional hydrocarbon membranes that swell and degrade under wet operating conditions. The result is a high-performance, cost-effective alternative to perfluorinated membranes like Nafion, with the added benefit of scalability and sustainability. The technology is designed for use in hydrogen-related applications including fuel cells, water electrolyzers, energy storage systems, transportation, power generation, and off-road equipment, offering a universal design principle that can be adapted across multiple membrane chemistries. With a TRL of 3 and a U.S. patent pending, the technology is available for licensing through Los Alamos National Laboratory’s commercialization program, with opportunities for exclusive or non-exclusive agreements to companies interested in advancing next-generation electrochemical devices. The licensing opportunity is open until August 31, 2026, and interested parties are encouraged to contact licensing@lanl.gov for further details.

Plastics Material and Resin Manufacturing

POSTED

DEADLINE

in about 1 month

TECHNOLOGY LICENSING OPPORTUNITY: ChronoQuantum Fiber Timing Integrity MonitorChronoQuantum is a quantum-based timing integrity monitor developed by Los Alamos National Laboratory that adds a trusted, independent layer of timing verification to existing fiber-linked precision timing networks without replacing them. Leveraging correlated photon pairs distributed through the same optical infrastructure used by standard synchronization protocols like White Rabbit and PTP, it detects, classifies, and localizes residual timing drift in real time by analyzing the temporal and spectral fingerprints of photon coincidence events. This physics-driven approach reveals issues hidden from conventional telemetry, identifying whether errors originate from endpoint electronics, fiber path conditions, optical filters, or environmental factors, and provides calibrated uncertainty measurements alongside actionable insights. The system operates at telecom wavelengths, integrates seamlessly with existing DWDM equipment, and scales from simple two-node links to complex mesh and facility-scale deployments with redundant components and failover support. The platform enhances operational resilience through flexible modes ranging from passive monitoring to autonomous correction recommendations, powered by optional AI that fuses temporal, spectral, and spatial data to turn fragile quantum measurements into operational intelligence. Designed for high-stakes environments, it targets applications in high energy physics, quantum networking, telecommunications backhaul, GNSS backup systems, and scientific sensing arrays where microsecond or nanosecond timing precision is critical. Currently at TRL 3 with a U.S. patent pending, the technology is available exclusively or non-exclusively through Los Alamos National Laboratory’s licensing program, targeting companies seeking to advance timing assurance capabilities in fiber networks without overhaul of existing infrastructure. Interested parties may engage through the designated licensing contacts at licensing@lanl.gov by the response deadline of August 7, 2026.

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

TECHNOLOGY LICENSING OPPORTUNITY: Electrically Pumped Nanocrystal Laser DiodeThe Electrically Pumped Nanocrystal Laser Diode is a breakthrough laser technology developed at Los Alamos National Laboratory that enables efficient, room-temperature lasing using solution-processed colloidal quantum dots, overcoming decades-long challenges in electrically driven nanocrystal lasers. By addressing fundamental issues such as nonradiative Auger recombination, excessive heat generation at high current densities, and optical losses in traditional device architectures, the innovation integrates engineered nanocrystals with a heat-managed, current-focusing design and a low-loss photonic waveguide to achieve stable optical gain. This platform supports scalable, low-cost manufacturing compatible with printed electronics and on-chip integration, making it uniquely suited for next-generation optoelectronic systems without relying on conventional semiconductor fabrication methods. The technology opens access to compact, high-performance laser sources for a broad range of applications including optical communications, silicon photonics, sensing, defense systems, consumer electronics, and medical diagnostics. Its versatility extends to optical amplifiers and integrated photonic circuits, enabling miniaturized coherent light sources for applications from lidar and free-space communication to biomedical imaging and wearable devices. Currently at TRL 4 with a U.S. patent pending, the technology is being offered for licensing through Los Alamos National Laboratory, with opportunities for exclusive or non-exclusive agreements available to companies seeking to commercialize this disruptive platform. Proposals must be submitted by October 1, 2026, and inquiries should be directed to the designated licensing contacts at LANL.

Semiconductor and Related Device Manufacturing

POSTED

DEADLINE

TECHNOLOGY LICENSING OPPORTUNITY: Multi-Channel Atomic Magnetometer (MCAM)The Multi-Channel Atomic Magnetometer (MCAM) is a breakthrough non-cryogenic optical quantum sensor that delivers SQUID-level sensitivity to ultra-faint biomagnetic signals using a single shared vapor cell and optical system to generate up to 16 independent sensing channels simultaneously, eliminating the need for multiple independent sensor units. Unlike traditional systems that rely on liquid helium-cooled SQUIDs, MCAM operates at room temperature using a large alkali-metal vapor cell, broad pump and probe laser beams, and a photodiode array to detect magnetic field-induced polarization rotations via the Faraday effect. Buffer gas within the cell isolates spatial regions behind each photodiode pixel, enabling high-resolution, two-dimensional magnetic field mapping without cryogens, significantly reducing costs and complexity. The rear-mirror optical design shortens the sensor-to-source distance, enhancing spatial resolution, while fiber-optic coupling allows modules to be tiled into conformal helmet or surface arrays that adapt to patient anatomy, supporting applications from brain and heart imaging to pediatric and point-of-care diagnostics. MCAM’s architecture scales efficiently to hundreds of channels and is compatible with adjustable bias coils and multiple alkali-metal and buffer-gas combinations, making it highly flexible for diverse configurations. It achieves sensitivity in the low tens of femtotesla per root hertz at low frequencies while drastically cutting per-channel expenses by sharing critical components across all channels. Ongoing development aims to shrink the effective sensing volume from centimeter to micrometer scale, opening the door to cellular-level magnetic imaging—capabilities unattainable by current cryogenic or conventional room-temperature systems. Applications span medical diagnostics such as magnetoencephalography and magnetocardiography, cancer detection via magnetic particle imaging, low-field MRI, geomagnetic surveying, and fundamental physics research. The technology, protected by U.S. Patent 11,105,865 and currently at TRL 4, is available for licensing through Los Alamos National Laboratory, offering exclusive and non-exclusive opportunities to commercialize a platform poised to revolutionize biomagnetic sensing by making high-performance imaging accessible, mobile, and cost-effective.

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

Unable to decompose prime contract due to authentication failureAccess to the prime contract details is currently restricted due to an authentication failure, preventing any decomposition or analysis of the underlying solicitation. Despite this, the subcontract opportunity is listed under the Department of Energy, with Triad as the DOE contractor, and is tied to a performance location in Los Alamos, New Mexico, with the zip code 87545. The posting date is July 8, 2026, and responses are due by October 1, 2026, but no solicitation number, NAICS code, set-aside details, or point of contact information is available. The opportunity remains in a pending state, with no supplier or subcontractor opportunities discernible until authentication rights are restored and the prime contract data becomes accessible.

POSTED

DEADLINE

Technology Licensing & Commercialization SupportThe contract supports the market deployment of UltraSep through a comprehensive strategy focused on licensing, regulatory compliance, and partnership development, aiming to accelerate its commercialization across relevant industries. The work will involve establishing licensing agreements to enable third-party adoption, navigating federal and industry-specific regulatory frameworks to ensure lawful and efficient market entry, and forging strategic alliances with industry stakeholders to expand reach and scalability. All activities are centered on translating the UltraSep technology from development into widespread practical application. The subcontract is administered by Triad, a Department of Energy contractor, with performance based in Los Alamos, New Mexico, under NAICS code 541611 for scientific research and development services. The opportunity was posted on July 8, 2026, with a response deadline of October 1, 2026, and is open to qualified entities seeking to contribute to advanced technology commercialization efforts under the DOE’s broader innovation and deployment goals. No set-aside provisions are specified, and while the point of contact details are unavailable, interested parties must submit proposals through the designated federal procurement portal prior to the stated deadline.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Pilot-Scale System Fabrication & AssemblyThe contract calls for the fabrication and assembly of modular, pilot-scale UltraSep units designed for field testing in industrial settings, with performance focused on real-world operational environments. Work is to be conducted at a designated location in Los Alamos, New Mexico, with a deadline for submission of proposals set for October 1, 2026. This is a subcontract under the Department of Energy’s oversight through its contractor Triad, and it falls under the NAICS code 332999 for other miscellaneous fabricated metal product manufacturing, indicating a specialized, non-standard manufacturing scope. The units are intended to serve as prototypes for evaluating advanced separation technologies at a scale relevant to industrial application, bridging laboratory development with field deployment readiness. While no set-aside details or point of contact are provided, the emphasis is on precision engineering, modular construction, and readiness for deployment in demanding industrial conditions.

All Other Miscellaneous Fabricated Metal Product Manufacturing

POSTED

DEADLINE

Chemistry-Enhanced Separation Reagent SupplyThe contract requires the supply of specialized chemical additives designed to enhance particle agglomeration or modify surface charge properties to improve the efficiency of acoustic separation processes. These reagents must be formulated to perform consistently under operational conditions typical in industrial or laboratory-scale separation systems where precise control over particle behavior is critical. The chemicals are intended for use in applications linked to Department of Energy objectives, likely involving material processing, waste remediation, or resource recovery where acoustic methods are employed to isolate or concentrate target particles. The subcontract is set to be awarded under NAICS code 325998 for other chemical product and preparation manufacturing, with performance required at Los Alamos, New Mexico, 87545. Proposals must be submitted by October 1, 2026, and the opportunity was posted on July 8, 2026. The contracting entity is Triad, acting as a DOE contractor, indicating the work supports federal energy mission goals. Suppliers must demonstrate technical capability in developing and delivering chemically advanced reagents with proven efficacy in acoustic environments and be prepared to meet stringent quality, reliability, and delivery expectations aligned with DOE standards.

All Other Miscellaneous Chemical Product and Preparation Manufacturing

POSTED

DEADLINE

Control Software Development & AI OptimizationTriad, acting as a DOE contractor, is seeking a subcontractor to develop real-time software for the acoustic separation process focused on eigenfrequency tracking, energy optimization, and closed-loop control. The project requires advanced software capable of dynamically adjusting system parameters in real time to enhance separation efficiency and reduce energy consumption through intelligent algorithmic adjustments. The software must integrate sensor data and feedback loops to continuously optimize the acoustic environment, ensuring precise control over resonant frequencies and energy distribution throughout the process. The work is to be performed at Los Alamos, New Mexico, with a response deadline of October 1, 2026, under a subcontract classified under NAICS code 541512 for computer systems design services. The project aims to advance DOE’s capabilities in acoustic processing through AI-driven automation and real-time adaptive control systems.

Computer Systems Design Services

POSTED

DEADLINE

Precision Ultrasonic Transducer ManufacturingThe contract calls for the precise manufacturing of high-frequency, tunable ultrasonic transducers designed specifically for integration into the UltraSep platform’s resonance-locked separation system, requiring advanced engineering to meet strict performance criteria under demanding operational conditions. These transducers must be capable of precise frequency adjustment to maintain resonance with the system’s separation mechanism, ensuring consistent and efficient material partitioning, with production expected to adhere to rigorous quality and repeatability standards suited for industrial-scale deployment. Performance of this subcontract is centered in Los Alamos, New Mexico, under the oversight of Triad, a contractor to the Department of Energy, with full compliance to NAICS code 334516 for other electronic component manufacturing. The opportunity was posted on July 8, 2026, and responses are due by October 1, 2026, indicating a targeted procurement timeline for qualified manufacturers with demonstrated expertise in piezoelectric systems and high-frequency transducer fabrication. All work must align with the technical requirements of the UltraSep platform, and potential bidders must possess the capability to deliver calibrated, reliable units suitable for integration into a sensitive, resonance-dependent separation process.

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

Acoustic System Engineering & Integration ServicesThe contract seeks specialized engineering services to design and integrate ultrasonic separation modules into industrial processing systems, with a focus on precision resonance tuning and closed-loop control implementation to optimize performance and reliability. Work involves developing and deploying advanced acoustic systems that enhance material separation efficiency in demanding operational environments, requiring deep expertise in acoustics, control systems, and industrial process integration. The project is positioned as a subcontract under Triad, the Department of Energy’s contractor, and is tied to research and development activities centered in Los Alamos, New Mexico, with a required performance location at 87545. The solicitation was posted in July 2026 and responses are due by October 1, 2026, under the NAICS code 541330, which classifies it as engineering services. There is no set-aside designation specified, indicating this opportunity is open to all qualified entities capable of delivering the technical scope required.

Engineering Services

POSTED

DEADLINE